Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (7736)	3/17/2000 1:19:00 PM
From: Biomaven	Read Replies (3) \| Respond to of 9719

Added to my MOGN last few days. Ovarian trials abstract at AACR looks great, albeit only with small numbers still: Publishing ID: 5470 PHASE II STUDY OF MGI-114 IN PLATINUM-RESISTANT RECURRENT OVARIAN CANCER. Lori Minasian, G. Sarosy, V. Dyer, S. Kim, D. R Kohler, A. Murgo, S. Smith, W. D Figg, E. Reed, National Cancer Inst, Bethesda, MD; MGI Pharma, Inc, Minneapolis, MN. MGI-114 (6-hydroxymethylacylfulvene) is a semi-synthetic analog of illudin S, extracted from Omphalotus illudens. We have initiated a phase II study of MGI-114 (11mg/m2/d, qd ž 4?5) in pts with ovarian cancer, recurrent or persistent after treatment with platinum and Taxol based chemotherapy. Eleven pts have been placed on study as of this writing ? all having platinum-resistant disease. (ECOG PFS 1?2; # Prior regimens 2?7). Three pts are too early to eval. One pt has progressive disease after 3 cycles of therapy; and three pts have withdrawn from study due to toxicity. That toxicity was grade III?IV malaise and fatigue. Other common toxicities were myelosuppression (platelets > wbc > rbc), and nausea/vomiting. Of four remaining pts, one has an ~60% reduction in disease after 6 cycles (liver primarily); one, an ~80% reduction after 4 cycles (lung primarily); one, an ~50% reduction after 4 cycles (liver and abd/pelvis, primarily); and one has a 44% reduction after 2 cycles of therapy (liver primarily). Therefore, 3 of 8 pts who received at least 2 cycles of therapy have acheived objective response; with another 3 continuing on therapy. We conclude that MGI-114 is an active agent in platinum-resistant ovarian cancer. Remember that these patients have already been through the wringer and then some - multiple treatment taxol/platinol failures. Thus the drop outs are possibly not all MGI-114's fault. This is a very tough patient population indeed. Peter